Horwitz, Steven Michael

Publications

Sort by

Co-Author Network

selected publications

Cancer worry and empathy moderate the effect of a survivorship-focused intervention on quality of life. Psycho-oncology. 2020 Academic Article GET IT
Times cited: 14
C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment. Histopathology. 2019 Academic Article GET IT
Fear of cancer recurrence in lymphoma survivors: A descriptive study. Journal of psychosocial oncology. 2019 Academic Article GET IT
Times cited: 11
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 11
Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center. Journal of the American Academy of Dermatology. 2019 Academic Article GET IT
Times cited: 32
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta haematologica. 2019 Academic Article GET IT
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019 Academic Article GET IT
Times cited: 81
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood cancer journal. 2019 Academic Article GET IT
Times cited: 81
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. American journal of hematology. 2019 Academic Article GET IT
Times cited: 30
Targeting CD47 in Sézary syndrome with SIRPαFc. Blood advances. 2019 Academic Article GET IT
Times cited: 83
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 48
Mycosis fungoides, Psoriasis und PD-1-Inhibitoren - neuer Aspekt einer bekannten Assoziation. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2019 Article GET IT
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 104
Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin. Journal of the American Academy of Dermatology. 2019 Academic Article GET IT
Times cited: 13
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019 Academic Article GET IT
Times cited: 117
Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. Blood advances. 2019 Academic Article GET IT
Times cited: 39
Immunotherapy in mycosis fungoides: opening night or dress rehearsal?. Leukemia & lymphoma. 2019 Article GET IT
Angioimmunoblastic T-Cell Lymphoma. Cancer treatment and research. 2019 Article GET IT
Times cited: 7
Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica. 2018 Academic Article GET IT
Times cited: 57
Mycosis fungoides, Psoriasis and Anti-PD-1 - A New Aspect of Known Associations. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2018 Article GET IT
Times cited: 1
Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center. The breast journal. 2018 Academic Article GET IT
Times cited: 12
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet (London, England). 2018 Academic Article GET IT
Times cited: 560
Novel Immunotherapies for T Cell Lymphoma and Leukemia. Current hematologic malignancy reports. 2018 Information Resource GET IT
Times cited: 24
Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature. Chinese clinical oncology. 2018 Information Resource GET IT
Times cited: 8
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American journal of hematology. 2018 Academic Article GET IT
Times cited: 51
Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial. Cancer. 2018 Academic Article GET IT
Times cited: 13
Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients. Journal of the European Academy of Dermatology and Venereology : JEADV. 2018 Academic Article GET IT
Times cited: 15
Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. American journal of hematology. 2018 Academic Article GET IT
Times cited: 35
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. The Lancet. Oncology. 2018 Academic Article GET IT
Times cited: 190
T-cell receptor-δ expression and γδ+ T-cell infiltrates in primary cutaneous γδ T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders. Histopathology. 2018 Academic Article GET IT
Times cited: 26
Peripheral T-cell lymphoma - are we making progress?. Best practice & research. Clinical haematology. 2018 Information Resource GET IT
Times cited: 4
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood cancer journal. 2018 Academic Article GET IT
Times cited: 28
Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer immunology research. 2018 Academic Article GET IT
Times cited: 76
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nature communications. 2018 Academic Article GET IT
Times cited: 79
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma. Blood advances. 2018 Academic Article GET IT
Times cited: 18
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. British journal of haematology. 2018 Academic Article GET IT
Times cited: 51
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018 Academic Article GET IT
Times cited: 116
Adult-Onset Still's Disease and Macrophage-Activating Syndrome Progressing to Lymphoma: A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special Surgery. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2018 Academic Article GET IT
Times cited: 4
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood. 2018 Academic Article GET IT
Times cited: 56
Association of Breast Implants With Anaplastic Large-Cell Lymphoma. JAMA oncology. 2018 Article GET IT
Times cited: 5
Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma. Bone marrow transplantation. 2018 Article GET IT
Times cited: 1
The optimal regimen of brentuximab vedotin for CD30⁺ cutaneous lymphoma: are we there yet?. The British journal of dermatology. 2017 Article GET IT
Times cited: 4
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2017 Academic Article GET IT
Times cited: 247
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood. 2017 Academic Article GET IT
Times cited: 217
Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study. Journal of the American Academy of Dermatology. 2017 Academic Article GET IT
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 56
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017 Academic Article GET IT
Times cited: 109
Clinical Outcome and Prognosis of Young Patients with Mycosis Fungoides. Pediatric dermatology. 2017 Academic Article GET IT
Times cited: 27
Adult T-Cell Leukemia/Lymphoma. Journal of oncology practice. 2017 Information Resource GET IT
Times cited: 55
Primary cutaneous marginal zone lymphoma with leptomeningeal involvement and a durable response to rituximab. 2017 GET IT
Times cited: 1
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet (London, England). 2017 Academic Article GET IT
Times cited: 278
Uncommon Variants of T-Cell Lymphomas. Hematology/oncology clinics of North America. 2017 Information Resource GET IT
Times cited: 2
Communication between oncologists and lymphoma survivors during follow-up consultations: A qualitative analysis. Journal of psychosocial oncology. 2017 Academic Article GET IT
Times cited: 9
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 20
Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 8
Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 20
Highlights in lymphoma from the 2016 American Society of Hematology annual meeting and exposition: Commentary. Clinical advances in hematology & oncology : H&O. 2017 Conference Paper GET IT
The Genetic Basis of Hepatosplenic T-cell Lymphoma. Cancer discovery. 2017 Academic Article GET IT
Times cited: 166
Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clinical lymphoma, myeloma & leukemia. 2017 Academic Article GET IT
Times cited: 12
T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Journal of the National Cancer Institute. 2016 Review GET IT
Times cited: 24
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?. Expert review of hematology. 2016 Information Resource GET IT
Times cited: 12
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Cancer medicine. 2016 Academic Article GET IT
Times cited: 16
A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. 2016 Academic Article GET IT
Times cited: 61
Targeting histone deacetylases in T-cell lymphoma. Leukemia & lymphoma. 2016 Information Resource GET IT
Times cited: 59
Long-term follow-up and management of small and medium-sized CD4⁺ T cell lymphoma and CD8⁺ lymphoid proliferations of acral sites: a multicenter experience. International journal of dermatology. 2016 Academic Article GET IT
Times cited: 35
Lenalidomide in Adult T-Cell Leukemia/Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Editorial Article GET IT
Times cited: 3
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Academic Article GET IT
Times cited: 59
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematological oncology. 2016 Article GET IT
Times cited: 41
Protocol for a cluster randomised trial of a communication skills intervention for physicians to facilitate survivorship transition in patients with lymphoma. BMJ open. 2016 Academic Article GET IT
Times cited: 14
Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides. Current hematologic malignancy reports. 2016 Information Resource GET IT
Times cited: 6
Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 46
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer cell. 2016 Academic Article GET IT
Times cited: 196
Central nervous system involvement in T-cell lymphoma: A single center experience. Acta oncologica (Stockholm, Sweden). 2016 Academic Article GET IT
Times cited: 40
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. Journal of hematology & oncology. 2016 Academic Article GET IT
Times cited: 40
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015 Academic Article GET IT
Times cited: 38
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. British journal of haematology. 2015 Academic Article GET IT
Times cited: 82
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 347
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 326
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 244
mTOR inhibition in T-cell lymphoma: a path(way) forward. Blood. 2015 Article GET IT
Times cited: 3
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 427
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 104
Survivorship care planning after participation in communication skills training intervention for a consultation about lymphoma survivorship. Translational behavioral medicine. 2015 Academic Article GET IT
Times cited: 9
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 152
Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Academic Article GET IT
Times cited: 13
Zebras and hen's teeth: recognition and management of rare T and NK lymphomas. Hematology. American Society of Hematology. Education Program. 2015 Academic Article GET IT
Times cited: 3
Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors. Pathology. 2014 Academic Article GET IT
Times cited: 62
Cutaneous manifestations of human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: a single-center, retrospective study. Journal of the American Academy of Dermatology. 2014 Academic Article GET IT
Times cited: 21
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomarker research. 2014 Academic Article GET IT
Times cited: 27
Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis. Leukemia. 2014 Article GET IT
Times cited: 67
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 150
Multicenter case series of indolent small/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face. The American Journal of dermatopathology. 2014 Academic Article GET IT
Times cited: 19
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014 Academic Article GET IT
Times cited: 298
Commentary. Clinical advances in hematology & oncology : H&O. 2014 Academic Article GET IT
Highlights in T-cell lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition: commentary. Clinical advances in hematology & oncology : H&O. 2014 Academic Article GET IT
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. Journal of the American Academy of Dermatology. 2014 Information Resource GET IT
Times cited: 223
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. Journal of the American Academy of Dermatology. 2014 Information Resource GET IT
Times cited: 156
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. Journal of hematology & oncology. 2014 Academic Article GET IT
Times cited: 178
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2013 Academic Article GET IT
Times cited: 339
Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 23
A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clinical lymphoma, myeloma & leukemia. 2013 Academic Article GET IT
Times cited: 32
Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification. Journal of the American Academy of Dermatology. 2013 Information Resource GET IT
Times cited: 70
Primary cutaneous B-cell lymphomas: part II. Therapy and future directions. Journal of the American Academy of Dermatology. 2013 Information Resource GET IT
Times cited: 37
Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?. Current treatment options in oncology. 2013 Academic Article GET IT
Times cited: 21
A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides. Journal of the American Academy of Dermatology. 2013 Academic Article GET IT
Times cited: 29
18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. Leukemia & lymphoma. 2013 Academic Article GET IT
Times cited: 61
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 174
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clinical lymphoma, myeloma & leukemia. 2012 Academic Article GET IT
Times cited: 65
Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Photodermatology, photoimmunology & photomedicine. 2012 Academic Article GET IT
Times cited: 30
Should patients with aggressive peripheral T-cell lymphoma all be treated the same?: no... well yes, ...but maybe not for long. Cancer journal (Sudbury, Mass.). 2012 Information Resource GET IT
Times cited: 8
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clinical lymphoma, myeloma & leukemia. 2012 Academic Article GET IT
Times cited: 38
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012 Academic Article GET IT
Times cited: 101
Highlights in T-cell lymphoma from the 2011 American Society of Hematology Annual Meeting and Exposition. Clinical advances in hematology & oncology : H&O. 2012 Conference Paper GET IT
Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 35
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 427
T-cell lymphomas in South america and europe. Revista brasileira de hematologia e hemoterapia. 2012 Academic Article GET IT
Times cited: 45
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2011 Academic Article GET IT
Times cited: 251
Peripheral T-cell lymphomas: diagnosis and treatment options. Proceedings from a live roundtable, August 17, 2011, Kauai, Hawaii. Clinical advances in hematology & oncology : H&O. 2011 Conference Paper GET IT
Times cited: 7
Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clinical lymphoma, myeloma & leukemia. 2011 Academic Article GET IT
Times cited: 73
Current treatment of peripheral T-cell lymphoma. Clinical advances in hematology & oncology : H&O. 2011 Information Resource GET IT
Times cited: 1
Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study. American journal of hematology. 2011 Academic Article GET IT
Times cited: 30
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 549
Inter-rater reliability of the Pediatric Transplant Rating Instrument (P-TRI): challenges to reliably identifying adherence risk factors during pediatric pre-transplant evaluations. Pediatric transplantation. 2011 Academic Article GET IT
Times cited: 8
Clinical roundtable monograph. The management of aggressive T-cell lymphoma: a discussion on transformed mycosis fungoides. Clinical advances in hematology & oncology : H&O. 2010 Academic Article GET IT
Times cited: 2
Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?. Current oncology reports. 2010 Information Resource GET IT
Times cited: 8
Characterization of T-cell lymphomas by FDG PET/CT. AJR. American journal of roentgenology. 2010 Academic Article GET IT
Times cited: 67
A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer. 2010 Academic Article GET IT
Times cited: 38
Clinical roundtable monograph. Current management and treatment of T-cell lymphoma: A multidisciplinary approach. Clinical advances in hematology & oncology : H&O. 2010 Academic Article GET IT
T-cell lymphoma: Where we are going. Clinical Advances in Hematology and Oncology. 2010 Article
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 287
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 170
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clinical pharmacology and therapeutics. 2009 Academic Article GET IT
Times cited: 35
Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. Journal of the American Academy of Dermatology. 2008 Academic Article GET IT
Times cited: 37
Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. Journal of the National Comprehensive Cancer Network : JNCCN. 2008 Information Resource GET IT
Times cited: 90
Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. Hematology. American Society of Hematology. Education Program. 2008 Academic Article GET IT
Times cited: 14
Rare T-cell lymphomas. Cancer treatment and research. 2008 Article GET IT
Times cited: 1
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. British journal of haematology. 2007 Academic Article GET IT
Times cited: 73
Management of peripheral T-cell non-Hodgkin's lymphoma. Current opinion in oncology. 2007 Information Resource GET IT
Times cited: 22
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 217
Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer. 2007 Academic Article GET IT
Times cited: 69
Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leukemia & lymphoma. 2007 Academic Article GET IT
Times cited: 62
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2006 Academic Article GET IT
Times cited: 258
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 358
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. British journal of haematology. 2005 Academic Article GET IT
Times cited: 102
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leukemia & lymphoma. 2005 Academic Article GET IT
Times cited: 39
Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients. Archives of dermatology. 2004 Academic Article GET IT
Times cited: 39
Rituximab in stem cell transplantation for aggressive lymphoma. Current hematology reports. 2004 Information Resource GET IT
Times cited: 7
Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. British journal of haematology. 2004 Academic Article GET IT
Times cited: 53
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2003 Academic Article GET IT
Times cited: 199
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003 Academic Article GET IT
Times cited: 176
Advances in the treatment of Hodgkin's lymphoma. Current opinion in hematology. 2000 Information Resource GET IT
Times cited: 11
Gemcitabine is active in relapsed Hodgkin's disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Article GET IT
Times cited: 19
Three-dimensional computed tomography studies of the tendons of the foot and ankle. Journal of digital imaging. 1992 Academic Article GET IT
Times cited: 12

more ...

less ...

Background

education and training

M.D., Case Western Reserve University School of Medicine 1993
B.A., University of Michigan 1989

Contact

full name

Steven Michael Horwitz

VIVO Weill Cornell Medical College

Steven Michael Horwitz Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name